Abstract: Specific aspects of the cellular and humoral immune systems of a mammalian host are regulated by administering to the host a compound having a reactive immunoregulatory conformation whose precise three-dimensional structure is defined herein. Sorbinil, tolrestat, WF-3681, and the other immunoregulatory agents described herein process this reactive conformation and so are therapeutically useful for inhibiting delayed-type hypersensitivity, T-cell proliferation, and B-cell antibody production, without altering the normal cellularity of the immune system or the normal metabolites of the arachidonic acid pathway.

Abstract: A method is described for increasing the plasma L-Carnitine level in pets. A daily prophylactic amount of L-Carnitine is administered in the pet either as a dietary supplement in an amount of 0.2 to 2.0 grams of L-Carnitine per day, or L-Carnitine is provided as an additional ingredient to a commerical pet food in an amount of 0.2 to 2.0 grams of L-Carnitine per kilogram pet food.

Abstract: This invention relates to a pharmaceuticals which contains thyroid hormones and improved method which extracts thyroid hormones from animal thyroid gland. The pharmaceuticals of this invention is used to treat senile cortical cataract. There are some effect of long term on other cataract except subcapsular cataract. The pharmaceuticals of this invention is applied in the form of eyedrops or injection.

Abstract: Carnitine, aminocarnitine and cysteic acid serve as carriers to bring pharmaceutically active compounds to desired sites in the body, e.g. skeletal muscle or the heart. The pharmaceutically active compound can be a protease inhibitor, a cardioactive drug for combating arrythmia, etc. The linkage is chemical through one or more alcohol, carboxyl or amine groups using reagents such as glutaraldehyde, dicarboxylic acid anhydrides and acid halides and carbodiimides. Carnitine derivatives are also incorporated into liposomes which are then used as carriers of active pharmaceutical agents.

Abstract: Pharmaceutical compositions of the prodrug type, a process for the preparation thereof, a process for the preparation of the as prodrug functioning compounds and compounds obtained herein.The pharmaceutical compositions of the invention contain organic acid anhydrides with formula 1 through 5, as well as the pharmacological acceptable salts thereof as prodrug functioning compounds, together with a suitable pharmaceutically acceptable gaseous, liquid or solid carrier.The prodrug systems of the invention possess as favorable property that they amend the residence time of the pharmaceutical composition in the body by influencing the transport system.Furthermore they increase the biological availability because of the more lipophilic properties of the anhydride compared with the acid, so that this improved administration performance may contribute to lower dosages.

Abstract: The present invention provides a composition comprising L-carnitine in a suitable vehicle for topical application in an effective amount. The present compositions are useful in improving or healing skin conditions including wrinkling, dry or peeling skin, and burns (particularly sunburn), and in healing and prevention of scar formation, particlarly that caused by infection by a pathogen. Treatment methods are also provided.

Abstract: Use of a long chain alkyl ester as a temporary microbicide at pH-values from about 6 to about 8.5. The long-chain alkyl ester has the formula ##STR1## where R.sup.I, R.sup.II, and R.sup.III are hydrogen or lower alkyl groups and R.sup.IV is an long chain alkyl group having 10-18 carbon atoms, R.sup.V is hydrogen or a group having the formula R.sup.VI N.sup.+ H.sub.3 where R.sup.VI is an alkylene group having 3-4 carbon atoms, A is a monovalent counter ion and n is the number of cationic groups in the ester compound. The ester exhibits a temporary microbicidal effect due to a hydrolytic reaction. As a consequence the toxic effect on human and animals cells and tissues will be low.

Abstract: Novel pharmaceutical analgesic, anti-inflammatory and skeletal muscle relaxant compositions and methods of using same comprising an analgesically and anti-inflammatory effective amount of at least one non-steroidal anti-inflammatory drug other than aspirin, acetaminophen and phenacetin, in combination with an effective amount of a skeletal muscle relaxant.

Abstract: Intravenous administration of a bolus of 3-5 grams of acetyl L-carnitine, followed by 3-5 grams of acetyl L-carnitine via slow infusion in about 12 hours, dramatically restore to normal the arterial pressure and respiratory frequency of a patient in a severe state of shock.

Abstract: It has been found that certain derivatives of poly(diallylmethylamine) are therapeutically effective serum cholesterol lowering agents.

Abstract: The subject matter of the invention is an agent and a method for improving the condition of hair on the basis of a combination of 0.1 to 25.0% by weight of trimethyl ammonia acetate betaine of the formula (CH.sub.3).sub.3 N.sup..sym. --CH.sub.2 --COO.sup..crclbar. and 0.1 to 10.0% by weight of at least one aliphatic organic acid as a hair conditioning component. Preferred forms of preparations are a hair conditioning rinse, a hair conditioning emulsion, a hair treatment kit, or a hair strengthener.

Abstract: Oral or parenteral administration of 1,000-2,000 mg/day of acetyl L-carnitine or an equivalent amount of a pharmacologically acceptable salt thereof to patients affected by acute or chronic peripheral neuropathy dramatically improves their symptomatological pattern.

Abstract: The invention concerns novel pyruvate compounds namely L-lysine pyruvate and L-histidine pyruvate, the method for making these compounds by bringing together pyruvic fluid acid with L-lysine and L-histidine resp., and preparations containing L-lysine pyruvate and/or L-histidine pyruvate.

Abstract: Compounds having the formula: ##STR1##are antagonists of leukotrienes of C.sub.4, D.sub.4 and E.sub.4, the slow reacting substance of anaphylaxis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory agents and cytoprotective agents.

Abstract: Novel compounds, viz. 3-(2,2,2-trisubstituted hydrazinium) propionates have the following general formula: ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are an alkyl, a substituted alkyl, a substituted or unsubstituted aryl, an aralkyl or an unsaturated alkyl;R.sup.4, R.sup.5 are hydrogen or a lower alkyl; n is 0 to 2, except for the case where R.sup.1, R.sup.2 and R.sup.3 are methyl, R.sup.4 and R.sup.5 are not hydrogen.The compounds of the present invention possess both hypotensive and antiarrhythmic activity and are useful in medicine.

Abstract: This invention relates to therapeutic compositions containing betaine salts for the treatment of hangover and for the lowering of alcohol content in blood in human. Daily dose comprises oral administration of 1 to 30 g, associated with appropriate carrier. Optional ingredients are an analgesic, a buffering agent and caffeine.

Abstract: A novel therapeutical use of some alkanoyl L-carnitines, e.g. acetyl L-carnitine, is disclosed which, orally or parenterally administered, are effective in the treatment of symptoms of idiopathic Parkinson's disease.

Abstract: Further to the discovery that D-carnitine exerts an antagonistic effect versus the therapeutically advantageous effect of L-carnitine in the treatment of certain cardiac dysfunctions, a pharmaceutical composition is described for the treatment of such dysfunctions characterized by the fact that all the carnitine present therein is solely L-carnitine.

Abstract: Further to the discovery that D-carnitine exerts an antagonistic effect versus the therapeutically advantageous effect of L-carnitine in the treatment of certain cardiac dysfunctions, a pharmaceutical composition is described for the treatment of such dysfunctions characterized by the fact that all the carnitine present therein is solely L-carnitine.

Abstract: The invention relates to a pharmaceutical composition containing carnitine or acetylcarnitine and Coenzyme Q.sub.10 in ratios from 100:1 to 2:1, together with pharmaceutically acceptable eccipients.The pharmaceutical composition described is suitable for the treatment of tissue energetic and metabolic disorders, and especially of heart and blood vessels, occurring in atherosclerosis, in myocardial or coronaric insufficiency, in hypertension, in cerebral ischaemia and, in general, tissue anoxia.

Abstract: This invention relates to therapeutic compositions containing betaine salts for the treatment of hangover and for the lowering of alcohol content in blood in human. Daily dose comprises oral administration of 1 to 30 g, associated with appropriate carrier. Optional ingredients are an analgesic, a buffering agent and caffeine.

Abstract: Acylcarnitines used as drug absorption enhancing agents for orally and rectally administered drugs.

Abstract: Disclosed are cosmetic compositions for the hair, containing hydrogenated tallow N,N-dimethyl glycinate, in the form of aqueous, alcoholic or aqueous-alcoholic solutions.

Abstract: Physiologically active substance FA-5859 and its deacetyl compound represented by the formula: ##STR1## wherein R.sub.1 is a hydrogen atom or an acetyl group, are produced by a cultivation of a microorganism of the genus Emericella or Aspergillus (compound wherein R.sub.1 is an acetyl group) or by a method of chemical synthesis (compound wherein R.sub.1 is a hydrogen atom or an acetyl group).Said compounds or a salt thereof have excellent fatty acid degradation inhibiting activity and is useful as an antidiabetic agent in mammalian animals or as a biochemical reagent for studies on fatty acid metabolism.

Abstract: A method for the preparation of betaines is disclosed, the betaines having the general formulaR.sup.1 CONH(CH.sub.2).sub.x N.sup..sym. R.sup.2 R.sup.3 (CH.sub.2).sub.y COO.sup..crclbar.in whichR.sup.1 is the alkyl residue of a fatty acid with 6 to 18 carbon atoms,R.sup.2 and R.sup.3 are the same or different and represent alkyl residues with 1 to 4 carbon atoms,x=2 or 3, andy=1, 2 or 3.The betaines are prepared by quaternizing fatty acid amides having the formulaR.sup.1 CONH(CH.sub.2).sub.x NR.sup.2 R.sup.3with .omega.-halogenalkylcarboxylic acids having the formulaX(CH.sub.2).sub.y COOHwherein X is a halogen residue, and carrying out the quaternization at a pH of 7.5 to 10.5 measured at 98.degree. C. The reaction product obtained from the process is essentially free of unreacted amides and organically linked chlorine and thus avoids the skin irritations normally associated with compounds in which such betaines are used.